Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03697161 · ClinicalTrials.gov registry record · Phase 2
A Study of OV101 in Individuals With Fragile X Syndrome
A Phase 2 study, sponsored by Healx AI.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT03697161 is a Phase 2 study that has completed, run by Healx AI. The registered enrollment target is 36 participants.
The verdict
NCT03697161, a Phase 2 study, has completed, sponsored by Healx AI.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability and efficacy of oral OV101 (gaboxadol) in subjects with Fragile X syndrome.
Interventions
- DRUG OV101 (gaboxadol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2018-09-17 |
| Est. Completion | 2020-02-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03697161
The ClinicalTrials.gov registry entry for NCT03697161 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Healx AI, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OV101 (gaboxadol) is the first listed.
NCT03697161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03697161 about?
NCT03697161 is a clinical study titled "A Study of OV101 in Individuals With Fragile X Syndrome". The purpose of this study is to assess the safety, tolerability and efficacy of oral OV101 (gaboxadol) in subjects with Fragile X syndrome.
What is the current status of trial NCT03697161?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2018-09-17. Estimated completion is 2020-02-26.
What interventions are being tested in trial NCT03697161?
The interventions under investigation include: OV101 (gaboxadol) (DRUG).
Who is sponsoring clinical trial NCT03697161?
This trial is sponsored by Healx AI, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.